Amplification of HER2 gene is observed in 20–30% of human cancers, especially breast and ovarian cancers [1], and in about 30% of feline mammary carcinomas (FMCs) [2], while its overexpression is correlated with poor prognosis and worse clinical outcomes [3]. The gene discussed is ERBB2; the disease is cancer.